Literature DB >> 2691958

Characterization of the ros1-gene products expressed in human glioblastoma cell lines.

S Sharma1, C Birchmeier, J Nikawa, K O'Neill, L Rodgers, M Wigler.   

Abstract

Most glioblastoma-derived cell lines express an 8.3 kb ros1 transcript and a 280 kD glycoprotein designated gp280ros1, which can be specifically immunoprecipitated with an anti-ROS antibody. This 280 kD protein possesses in vitro autokinase activity and was observed in four independent glioblastoma cell lines. In a fifth glioblastoma cell line, U-118 MG, a smaller ros1 transcript of 4.0 kb was observed. Immunoprecipitation analysis reveals that the U-118 MG expressed a smaller, 116 kD ros1 gene product. cDNA cloning and sequencing of the U-118 MG ros1 transcript indicates it encodes the entire tyrosine kinase domain and two amino acids of the transmembrane domain of ros1 at its 3' end. Sequences at its 5' end likely arise from another gene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2691958

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  18 in total

1.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 2.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

3.  Two point mutations in the transmembrane domain of P68gag-ros inactive its transforming activity and cause a delay in membrane association.

Authors:  S M Jong; L H Wang
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

Review 4.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

5.  Characterization of ROS1 cDNA from a human glioblastoma cell line.

Authors:  C Birchmeier; K O'Neill; M Riggs; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

6.  Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Authors:  Anna Saborowski; Michael Saborowski; Monika A Davare; Brian J Druker; David S Klimstra; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-23       Impact factor: 11.205

7.  Altered chromosome 6 in immortal human fibroblasts.

Authors:  K Hubbard-Smith; P Patsalis; J R Pardinas; K K Jha; A S Henderson; H L Ozer
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

8.  Enhancement of transforming potential of human insulinlike growth factor 1 receptor by N-terminal truncation and fusion to avian sarcoma virus UR2 gag sequence.

Authors:  D Liu; W J Rutter; L H Wang
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

Review 9.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  Oncologist       Date:  2013-06-28

10.  Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.

Authors:  Monika A Davare; Jacob J Henderson; Anupriya Agarwal; Jacob P Wagner; Sudarshan R Iyer; Nameeta Shah; Randy Woltjer; Romel Somwar; Stephen W Gilheeney; Ana DeCarvalo; Tom Mikkelson; Erwin G Van Meir; Marc Ladanyi; Brian J Druker
Journal:  Clin Cancer Res       Date:  2018-08-31       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.